Research guide
Peptides for Muscle Building
A plain-language map of the compounds that appear most often in muscle-building and recovery literature — what pathway each one acts on, how the research pairs them, and the dosing ranges cited in published protocols. Everything here is for laboratory research use only.
How the research groups these compounds
Muscle-building research splits into two mechanisms that rarely get separated in casual discussion. The first is the GH/IGF-1 axis: growth-hormone releasing hormone analogs (CJC-1295, Tesamorelin) and selective secretagogues (Ipamorelin) raise endogenous GH signaling, which in turn raises IGF-1 — the pathway associated with protein synthesis, nutrient partitioning and connective-tissue turnover.
The second is repair and training continuity: BPC-157 and TB-500 are studied for angiogenesis, cell migration and soft-tissue healing. They do not drive hypertrophy directly, but the literature is interested in them because uninterrupted mechanical loading is the single largest variable in muscle accrual.
A focused research stack usually pulls one or two compounds from the first group and one from the second. Stacking four GH secretagogues together adds redundancy, not signal.
Compound reference
Dosing ranges below are the values cited in research literature, not recommendations.
CJC-1295 + Ipamorelin 5mg
GH secretagogueClassic blend pairing a GHRH analog with a selective ghrelin-receptor agonist; studied for amplified GH pulse amplitude with minimal cortisol/prolactin shift.
Research range: Commonly cited at 100–200 mcg of each, 1–2x daily before sleep.
- Route
- Not reproduced on this page — see the research-use disclaimer above.
- Frequency
- Not reproduced on this page — see the research-use disclaimer above.
- Timing
- Not reproduced on this page — see the research-use disclaimer above.
- Cycle length
- 8–12 week research blocks are commonly cited in the literature.
- Handling
- Handling, reconstitution and storage steps are not reproduced here; refer to the original published methodology.
Protocol reference
CJC-1295 with DAC
Long-acting GHRHDAC extends half-life for a sustained GH/IGF-1 baseline; used in research where fewer administrations are preferred.
Research range: Research literature cites 1–2 mg weekly.
- Route
- Not reproduced on this page — see the research-use disclaimer above.
- Frequency
- Not reproduced on this page — see the research-use disclaimer above.
- Timing
- Not reproduced on this page — see the research-use disclaimer above.
- Cycle length
- 8–12 week research blocks are commonly cited in the literature.
- Handling
- Handling, reconstitution and storage steps are not reproduced here; refer to the original published methodology.
Protocol reference
BPC-157
RepairPentadecapeptide widely studied for angiogenesis and connective-tissue repair signaling in tendon, ligament and gut models.
Research range: Commonly referenced at 250–500 mcg once or twice daily.
- Route
- Not reproduced on this page — see the research-use disclaimer above.
- Frequency
- Not reproduced on this page — see the research-use disclaimer above.
- Timing
- Not reproduced on this page — see the research-use disclaimer above.
- Cycle length
- 4–8 week research blocks are commonly cited in the literature.
- Handling
- Handling, reconstitution and storage steps are not reproduced here; refer to the original published methodology.
Protocol reference
TB-500 (Thymosin β4)
RepairActin-binding peptide studied for cell migration and systemic soft-tissue recovery; frequently paired with BPC-157 in research.
Research range: Research ranges of 2–5 mg weekly, often split into two doses.
- Route
- Not reproduced on this page — see the research-use disclaimer above.
- Frequency
- Not reproduced on this page — see the research-use disclaimer above.
- Timing
- Not reproduced on this page — see the research-use disclaimer above.
- Cycle length
- 4–6 week research blocks are commonly cited in the literature.
- Handling
- Handling, reconstitution and storage steps are not reproduced here; refer to the original published methodology.
Protocol reference
BPC-157 + TB-500 Blend
Repair stackPre-blended vial for research protocols combining local repair signaling with systemic cell-migration pathways.
Research range: Typically referenced as 250 mcg BPC / 500 mcg TB daily equivalents.
- Route
- Not reproduced on this page — see the research-use disclaimer above.
- Frequency
- Not reproduced on this page — see the research-use disclaimer above.
- Timing
- Not reproduced on this page — see the research-use disclaimer above.
- Cycle length
- 4–8 week research blocks are commonly cited in the literature.
- Handling
- Handling, reconstitution and storage steps are not reproduced here; refer to the original published methodology.
Protocol reference
Tesamorelin
GHRH analogGHRH analog most studied for reduction of visceral adipose tissue while supporting endogenous GH pulsatility.
Research range: Research ranges of 1–2 mg nightly are frequently cited.
- Route
- Not reproduced on this page — see the research-use disclaimer above.
- Frequency
- Not reproduced on this page — see the research-use disclaimer above.
- Timing
- Not reproduced on this page — see the research-use disclaimer above.
- Cycle length
- 12–26 week research blocks are commonly cited in the literature.
- Handling
- Handling, reconstitution and storage steps are not reproduced here; refer to the original published methodology.
Protocol reference
Example research pairings
- Lean-mass focus: CJC-1295 + Ipamorelin. A steady GHRH baseline plus selective pulses — the most frequently referenced GH-axis pairing in the literature.
- Growth with joint load: CJC-1295 + Ipamorelin with BPC-157. Adds repair signaling for tendon and ligament tissue under heavy training volume.
- Return from injury: BPC-157 + TB-500. Local repair signaling combined with systemic cell migration; also available as a pre-blended research vial.
- Recomposition: Tesamorelin alongside a GH secretagogue, studied for visceral-fat reduction while preserving lean tissue.
What the research does not show
None of these compounds substitute for training stimulus, protein intake or sleep. GH secretagogue studies consistently show effects on body composition markers rather than raw strength, and effects taper as endogenous signaling adapts. Longer is not better: research protocols are time-bound and cycled, and outcomes are measured against a controlled training variable.
Frequently asked questions
Which peptides are most studied for muscle building?
Growth-hormone secretagogues such as CJC-1295 and Ipamorelin are the most referenced muscle-building pair because they act on the GH/IGF-1 axis. Tesamorelin appears in body-composition research, while BPC-157 and TB-500 are studied for repair and training continuity.
Do peptides build muscle without training?
No. In published research, GH-axis signaling is a modifier of adaptation, not a replacement for mechanical tension, progressive overload, adequate protein and sleep. Studies pair compound administration with a resistance-training or rehabilitation stimulus.
Are CJC-1295 and Ipamorelin used together in research?
Frequently. CJC-1295 is a long-acting GHRH analog that raises the baseline GH signal, while Ipamorelin is a selective ghrelin-receptor secretagogue that produces pulses. The pairing is the most commonly referenced GH-axis research combination.
How does BPC-157 relate to muscle building?
Indirectly. BPC-157 is studied for angiogenesis and connective-tissue repair in tendon, ligament and gut models. Its relevance to hypertrophy research is training continuity — less time lost to soft-tissue irritation.
Are these compounds legal to buy?
The compounds discussed here are sold and referenced for laboratory research use only. They are not approved drugs, dietary supplements, or products for human or veterinary consumption.
Build a stack for your own goal
Answer three questions and the hub matches 2–4 compounds to your goal, experience level and focus areas.
Open the stack builderOr read the fat-loss research guide.
For research purposes only. Not intended for human consumption. Consult a qualified professional.
Research disclaimer: All compounds referenced on this page are intended for laboratory research use only. They are not drugs, dietary supplements, or products for human or veterinary consumption. Nothing here is medical advice, and no dosing figure is a recommendation. Consult a qualified physician before making any health decision.